Dupilumab (Dupixent) has been listed on the PBS from March 1 for the treatment of adolescent and adult patients with severe atopic dermatitis that has not responded to topical therapies. The long awaited listing of the monoclonal antibody comes after three applications to the PBAC, success at the March 2020 meeting, and a revisit in ...
Relief at last: dupilumab on the PBS for atopic dermatitis
By Mardi Chapman
3 Mar 2021